Literature DB >> 7054027

Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma.

J P Wright, G O Young, L J Klaff, L A Weers, S K Price, I N Marks.   

Abstract

Prostaglandin E was measured by radioimmunoassay in endoscopic biopsy specimens obtained from 7 normal healthy volunteers, 28 patients with a benign gastric ulcer, and 10 with a malignant gastric ulcer. Biopsy specimens were taken from the antral and body mucosa and from the ulcer edge in patients. The median value in normal antrum specimens was 5.15 (4.44-8.40) ng PGE/mg protein which was more than the body with 3.50 (1.86-9.28), p less than 0.05. In the 28 patients with benign gastric ulcer the ulcer edge contained 2.33 (0.48-7.67) ng PGE/mg protein which was more than the antrum with 1.06 (0.30-4.17) or the body with 0.97 (0.20-7.67), p less than 0.01 respectively. The antral and body levels in patients with gastric ulcers were lower than those found in the normal volunteers, p less than 0.01. There was no difference between the levels found in patients with malignant as opposed to benign gastric ulcer. In patients with gastric ulcer lower levels of PGE were found in body mucosa with atrophic gastritis 0.83 (0.53-2.66) ng PGE/mg protein as compared with histologically normal body mucosa 2.55 (0.63-7.67), p less than 0.05. These results suggest that mucosal PGE levels are reduced in patients with gastric ulcer disease and that this may be due to the presence of atrophic gastritis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7054027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  Role of leukotrienes in hydrochloric acid-induced gastric lesions in rats.

Authors:  T Osada; H Goto; Y Tsukamoto; S Nakazawa; S Sugiyama; T Ozawa
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

2.  Effects of secretin on content of PGE2 and 6-keto PGF1 alpha in gastric mucosa.

Authors:  T Mine; J Fujisaki; K Akimoto; S Yoshida; Y Hasegawa; E Ogata
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

3.  Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins.

Authors:  T Arakawa; T Watanabe; T Fukuda; K Higuchi; O Takaishi; K Yamasaki; K Kobayashi; A Tarnawski
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  The pathophysiology of peptic ulcer disease.

Authors:  F P Brooks
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Prostaglandins in peptic ulcer disease. An overview of current status and future directions.

Authors:  S J Sontag
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

6.  Catecholamine concentrations in biopsied gastroduodenal tissue specimens of patients with duodenal ulcer.

Authors:  M Kaise; H Echizen; N Umeda; T Ishizaki
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

7.  Sample taking problems in measuring actual histamine levels of human gastroduodenal mucosa: specific and general relevance in clinical trials on peptic ulcer pathogenesis and selective proximal vagotomy.

Authors:  K P Thon; W Lorenz; C Ohmann; D Weber; H Rohde; H D Röher
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

8.  Role of prostaglandins in the early phases of experimental gastric carcinogenesis in the rat.

Authors:  A Materia; G Silecchia; E Spaziani; P Mariani; L Scucchi; P Mingazzini; C Favalli; E Garaci; N Basso
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

9.  Cigarette smoking reduces human gastric luminal prostaglandin E2.

Authors:  D R McCready; L Clark; M M Cohen
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

10.  Prostaglandins in pathophysiology of peptic ulcer disease.

Authors:  S J Konturek
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.